BP
HOLX

Ballentine Partners’s Hologic HOLX Stock Holding History

Ballentine Partners’s Portfolio HOLX Stock Details HOLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,789
Closed -$211K – 1104
2026
Q1 		$211K Buy
+2,789
New +$210K ﹤0.01% 916
2025
Q1 		– Sell
-4,771
Closed -$344K – 949
2024
Q4 		$344K Buy
4,771
+139
+3% +$10.9K 0.01% 546
2024
Q3 		$377K Buy
4,632
+741
+19% +$59.3K 0.01% 506
2024
Q2 		$289K Sell
3,891
-50
-1% -$3.75K 0.01% 574
2024
Q1 		$307K Buy
3,941
+273
+7% +$20.3K 0.01% 528
2023
Q4 		$262K Buy
+3,668
New +$255K 0.01% 542
2017
Q1 		– Sell
-6,222
Closed -$216K – 262
2016
Q4 		$216K Sell
6,222
-207
-3% -$7.99K 0.02% 169
2016
Q3 		$250K Buy
6,429
+219
+4% +$8.27K 0.02% 159
2016
Q2 		$215K Buy
6,210
+51
+0.8% +$1.77K 0.02% 196
2016
Q1 		$212K Buy
+6,159
New +$215K 0.02% 197

Other funds holding HOLX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ballentine Partners's HOLX Position: Q2 2026 in Review

Ballentine Partners sold out of Hologic (HOLX) in Q2 2026, closing a stake of 2,789 shares — an estimated $211K sold.

Ballentine Partners first reported a position in HOLX in Q1 2016 and held it in 10 quarters. The position peaked at $377K in Q3 2024. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.

  • Ballentine Partners reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
  • Ballentine Partners sold 2,789 Hologic shares in Q2 2026, an estimated $211K.
  • Ballentine Partners first reported a position in Hologic in Q1 2016 and held it in 10 quarters.
  • Ballentine Partners's Hologic position peaked at $377K in Q3 2024.
  • 3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.